Form 4: Marker Therapeutics Director Granted Stock Options

Marker Therapeutics Director Katharine Knobil received grants of 221,741 stock options as compensation for her service.

Summary

• Katharine Knobil, a Director of Marker Therapeutics, Inc. (MRKR), was granted a total of 221,741 stock options.
• The grants occurred on November 17, 2025, with an exercise price of $0.9548 per share.
• One grant of 84,411 options represents the remaining portion of her 2024 director service compensation, following a previous grant of 30,000 shares on February 12, 2025.
• A second grant of 137,330 options is for her service as a director for the year 2025.
• All options were granted under the Company's 2020 Omnibus Stock Ownership Plan.
• The options vest on the anniversary of the grant date and have an expiration date of November 17, 2035.

Sentiment

Score: 6

Explanation: The filing reports routine stock option grants to a director, which is a standard compensation practice and aligns the director's interests with shareholders, indicating a neutral to slightly positive sentiment.

Positives

• The granting of stock options aligns the director's financial interests with the long-term performance and shareholder value of Marker Therapeutics, Inc.

Future Outlook

The granted stock options will vest on the anniversary of the grant date, providing future equity incentives for the director.

Industry Context

This filing represents a routine insider transaction related to director compensation, which is a standard practice across publicly traded companies to incentivize and align management and director interests with shareholders.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a common practice in the biotechnology and pharmaceutical industry, similar to companies like Gilead Sciences or Amgen, to attract and retain experienced board members and align their incentives with long-term company performance.

Corporate Governance

Related Party Transactions

• The grants of stock options to Director Katharine Knobil constitute a related party transaction as part of her compensation for service on the board.

Stakeholder Impact

• Shareholders: The grants align the director's incentives with shareholder interests, potentially fostering long-term value creation.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The granted stock options will vest annually on the anniversary of the grant date (November 17th).

Key Dates

Recommendation

This Form 4 reports routine director compensation in the form of stock options, which is not typically a catalyst for a change in investment recommendation. It reflects standard corporate governance practices and does not provide new information that would significantly alter the company's fundamental outlook or valuation.

Keywords

Marker Therapeutics, MRKR, stock options, director compensation, insider transaction, equity grant, Form 4